Idiopathic Inflammatory Myositis (IIM) clinical trials at UCSF

1 research study open to eligible people

Idiopathic inflammatory myositis (IIM) leads to the inflammation of muscles for unknown reasons. UCSF is testing a treatment called FT819 in people with B-cell autoimmune diseases. The trial checks if this treatment is safe and studies its behavior in the body.

Showing trials for

  • FT819 in B-cell Mediated Autoimmune Disease

    open to eligible people ages 12-70

    This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.

    San Francisco, California and other locations

Last updated: